This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Gerson JN , Handorf E , Villa D , Gerrie AS , Chapani P , Li S , Medeiros LJ , Wang MI , Cohen JB , Calzada O , Churnetski MC , Hill BT , Sawalha Y , Hernandez-Ilizaliturri FJ , Kothari S , Vose JM , Bast MA , Fenske TS , Narayana Rao Gari S , Maddocks KJ , Bond D , Bachanova V , Kolla B , Chavez J , Shah B , Lansigan F , Burns TF , Donovan AM , Wagner-Johnston N , Messmer M , Mehta A , Anderson JK , Reddy N , Kovach AE , Landsburg DJ , Glenn M , Inwards DJ , Karmali R , Kaplan JB , Caimi PF , Rajguru S , Evens A , Klein A , Umyarova E , Pulluri B , Amengual JE , Lue JK , Diefenbach C , Fisher RI , Barta SK
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
J Clin Oncol. 2019 Feb 20;37(6) :471-480
PMID: 30615550 URL: https://www.ncbi.nlm.nih.gov/pubmed/30615550
AbstractPURPOSE: Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND METHODS: We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score-weighted (PSW) analysis were performed. RESULTS: Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2). CONCLUSION: In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.
Notes1527-7755 Gerson, James N Handorf, Elizabeth Villa, Diego Gerrie, Alina S Chapani, Parv Li, Shaoying Medeiros, L Jeffrey Wang, Michael I Cohen, Jonathon B Calzada, Oscar Churnetski, Michael C Hill, Brian T Sawalha, Yazeed Hernandez-Ilizaliturri, Francisco J Kothari, Shalin Vose, Julie M Bast, Martin A Fenske, Timothy S Narayana Rao Gari, Swapna Maddocks, Kami J Bond, David Bachanova, Veronika Kolla, Bhaskar Chavez, Julio Shah, Bijal Lansigan, Frederick Burns, Timothy F Donovan, Alexandra M Wagner-Johnston, Nina Messmer, Marcus Mehta, Amitkumar Anderson, Jennifer K Reddy, Nishitha Kovach, Alexandra E Landsburg, Daniel J Glenn, Martha Inwards, David J Karmali, Reem Kaplan, Jason B Caimi, Paolo F Rajguru, Saurabh Evens, Andrew Klein, Andreas Umyarova, Elvira Pulluri, Bhargavi Amengual, Jennifer E Lue, Jennifer K Diefenbach, Catherine Fisher, Richard I Barta, Stefan K Journal Article United States J Clin Oncol. 2019 Feb 20;37(6):471-480. doi: 10.1200/JCO.18.00690. Epub 2019 Jan 7.